{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:40:47Z","timestamp":1762530047940,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.adro.2019.05.005","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T12:10:33Z","timestamp":1558440633000},"page":"641-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study"],"prefix":"10.1016","volume":"4","author":[{"given":"Hannah M.","family":"Dahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.K.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Cherpak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3173-0949","authenticated-orcid":false,"given":"Alasdair","family":"Syme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4391-4705","authenticated-orcid":false,"given":"Nikhilesh","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9932-7067","authenticated-orcid":false,"given":"David","family":"Bowes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2019.05.005_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.brachy.2017.10.001","article-title":"Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy","volume":"17","author":"Mendez","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2019.05.005_bib3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2019.05.005_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2019.05.005_bib5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2007.04.011","article-title":"High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial","volume":"84","author":"Hoskin","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2019.05.005_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.radonc.2018.10.020","article-title":"High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer","volume":"132","author":"Yamazaki","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2019.05.005_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.21037\/tau.2017.12.08","article-title":"High dose-rate brachytherapy in the treatment of prostate cancer","volume":"7","author":"Mendez","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.adro.2019.05.005_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ijrobp.2014.11.018","article-title":"Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: A propensity score matched analysis","volume":"91","author":"Smith","year":"2015","journal-title":"Int J\u00a0Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2019.05.005_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17434440.2018.1419058","article-title":"Prostate cancer high dose-rate brachytherapy: Review of evidence and current perspectives","volume":"15","author":"Dutta","year":"2018","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.adro.2019.05.005_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bju.12514","article-title":"Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer","volume":"114","author":"Spratt","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2019.05.005_bib11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2016.06.046","article-title":"Clinical outcomes for patients with Gleason score 9-10 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: A multi-institutional comparative analysis","volume":"71","author":"Kishan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2019.05.005_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.brachy.2017.06.013","article-title":"High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes","volume":"16","author":"Falk","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2019.05.005_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br J Radiol"},{"key":"10.1016\/j.adro.2019.05.005_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2019.05.005_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5114\/jcb.2014.45759","article-title":"High-dose-rate brachytherapy boost for prostate cancer: Rationale and technique","volume":"6","author":"Morton","year":"2014","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.adro.2019.05.005_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clon.2017.01.042","article-title":"Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer","volume":"29","author":"Shahid","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.adro.2019.05.005_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2015.02.023","article-title":"High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success","volume":"115","author":"Helou","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2019.05.005_bib18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.radonc.2017.10.039","article-title":"Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial","volume":"126","author":"Gomez-Iturriaga","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2019.05.005_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2019.05.005_bib20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5114\/jcb.2016.59216","article-title":"Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: Dosimetrics and early clinical results","volume":"8","author":"Lauche","year":"2016","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.adro.2019.05.005_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ijrobp.2009.05.054","article-title":"Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: Analysis of short- and medium-term toxicity and quality of life","volume":"77","author":"Morton","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2019.05.005_bib22","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ijrobp.2016.06.026","article-title":"Initial report of NRG Oncology\/RTOG 0232: A phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma","volume":"96","author":"Prestidge","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2019.05.005_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2019.02.010","article-title":"Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer","author":"Siddiqui","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2019.05.005_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrurol.2015.283","article-title":"Prostate cancer: Elective pelvic nodal radiotherapy: Is the jury still out?","volume":"13","author":"Crook","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.adro.2019.05.005_bib25","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ijrobp.2015.09.006","article-title":"Survival outcomes of whole-pelvic versus prostate-only radiation therapy for high-risk prostate cancer patients with use of the National Cancer Data Base","volume":"93","author":"Amini","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2019.05.005_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","article-title":"Toxicity and patient-reported outcomes of a Phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL)","volume":"103","author":"Dearnaley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2019.05.005_bib27","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.ijrobp.2017.07.041","article-title":"Phase 1\/2 dose-escalation study of the use of intensity modulated radiation therapy to treat the prostate and pelvic nodes in patients with prostate cancer","volume":"99","author":"Reis Ferreira","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109419300594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109419300594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:36:24Z","timestamp":1762529784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109419300594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2452109419300594"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2019.05.005","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2019.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}